Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
etoposide oral
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(33)
News
Trials
Company:
Generic mfg.
Drug class:
Topoisomerase II inhibitor, DNA inhibitor
Related drugs:
‹
doxorubicin hydrochloride (87)
etoposide IV (53)
pegylated liposomal doxorubicin (31)
epirubicin (29)
daunorubicin (20)
cytarabine/daunorubicin liposomal formulation (19)
idarubicin hydrochloride (16)
mitoxantrone (16)
dactinomycin (8)
teniposide (5)
MM-302 (4)
pixantrone (4)
non-pegylated liposomal doxorubicin (3)
pegylated liposomal doxorubicin (1)
IT-141 (1)
SGN-15 (1)
VLS-211 (1)
zoptarelin doxorubicin (1)
RTA 744 (1)
AVA6000 (0)
amsacrine (0)
amrubicin (0)
mitoxantrone liposomal (0)
H-ferritin–nanocaged doxorubicin (0)
HF158K1 (0)
MNPR-202 (0)
non-pegylated liposomal doxorubicin (0)
vosaroxin (0)
amonafide (0)
SQ3370 (0)
THE001 (0)
lyso-thermosensitive liposomal doxorubicin (0)
tirapazamine (0)
idronoxil (0)
INNO-206 (0)
MNPR-201 (0)
NSC311152 (0)
dexrazoxane (0)
SA033 (0)
doxorubicin liposomal (0)
2X-111 (0)
NP-ACT D (0)
valrubicin (0)
trabectedin (24)
CLR 131 (2)
estramustine (0)
laromustine (0)
IPdR (0)
doxorubicin hydrochloride (87)
etoposide IV (53)
pegylated liposomal doxorubicin (31)
epirubicin (29)
daunorubicin (20)
cytarabine/daunorubicin liposomal formulation (19)
idarubicin hydrochloride (16)
mitoxantrone (16)
dactinomycin (8)
teniposide (5)
MM-302 (4)
pixantrone (4)
non-pegylated liposomal doxorubicin (3)
pegylated liposomal doxorubicin (1)
IT-141 (1)
SGN-15 (1)
VLS-211 (1)
zoptarelin doxorubicin (1)
RTA 744 (1)
AVA6000 (0)
amsacrine (0)
amrubicin (0)
mitoxantrone liposomal (0)
H-ferritin–nanocaged doxorubicin (0)
HF158K1 (0)
MNPR-202 (0)
non-pegylated liposomal doxorubicin (0)
vosaroxin (0)
amonafide (0)
SQ3370 (0)
THE001 (0)
lyso-thermosensitive liposomal doxorubicin (0)
tirapazamine (0)
idronoxil (0)
INNO-206 (0)
MNPR-201 (0)
NSC311152 (0)
dexrazoxane (0)
SA033 (0)
doxorubicin liposomal (0)
2X-111 (0)
NP-ACT D (0)
valrubicin (0)
trabectedin (24)
CLR 131 (2)
estramustine (0)
laromustine (0)
IPdR (0)
›
Associations
(33)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
No biomarker
Thymic Carcinoma
No biomarker
Thymic Carcinoma
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
carboplatin + etoposide oral + bendamustine
Sensitive: A2 - Guideline
carboplatin + etoposide oral + bendamustine
Sensitive
:
A2
carboplatin + etoposide oral + bendamustine
Sensitive: A2 - Guideline
carboplatin + etoposide oral + bendamustine
Sensitive
:
A2
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
ifosfamide + etoposide oral + mitoxantrone
Sensitive: A2 - Guideline
ifosfamide + etoposide oral + mitoxantrone
Sensitive
:
A2
ifosfamide + etoposide oral + mitoxantrone
Sensitive: A2 - Guideline
ifosfamide + etoposide oral + mitoxantrone
Sensitive
:
A2
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
No biomarker
T Acute Lymphoblastic Leukemia
No biomarker
T Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
No biomarker
Merkel Cell Carcinoma
No biomarker
Merkel Cell Carcinoma
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
No biomarker
Kaposi Sarcoma
No biomarker
Kaposi Sarcoma
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
ifosfamide + methotrexate + etoposide oral
Sensitive: A2 - Guideline
ifosfamide + methotrexate + etoposide oral
Sensitive
:
A2
ifosfamide + methotrexate + etoposide oral
Sensitive: A2 - Guideline
ifosfamide + methotrexate + etoposide oral
Sensitive
:
A2
No biomarker
Testicular Cancer
No biomarker
Testicular Cancer
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
No biomarker
Medulloblastoma
No biomarker
Medulloblastoma
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
etoposide oral
Sensitive: A2 - Guideline
etoposide oral
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
cisplatin + etoposide oral
Sensitive: A2 - Guideline
cisplatin + etoposide oral
Sensitive
:
A2
cisplatin + etoposide oral
Sensitive: A2 - Guideline
cisplatin + etoposide oral
Sensitive
:
A2
No biomarker
Cervical Cancer
No biomarker
Cervical Cancer
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
carboplatin + etoposide oral
Sensitive: A2 - Guideline
carboplatin + etoposide oral
Sensitive
:
A2
No biomarker
Cervical Cancer
No biomarker
Cervical Cancer
cisplatin + etoposide oral
Sensitive: A2 - Guideline
cisplatin + etoposide oral
Sensitive
:
A2
cisplatin + etoposide oral
Sensitive: A2 - Guideline
cisplatin + etoposide oral
Sensitive
:
A2
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
ifosfamide + etoposide oral + mitoxantrone
Sensitive: A2 - Guideline
ifosfamide + etoposide oral + mitoxantrone
Sensitive
:
A2
ifosfamide + etoposide oral + mitoxantrone
Sensitive: A2 - Guideline
ifosfamide + etoposide oral + mitoxantrone
Sensitive
:
A2
No biomarker
Medulloblastoma
No biomarker
Medulloblastoma
cyclophosphamide + etoposide oral
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral
Sensitive
:
A2
cyclophosphamide + etoposide oral
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral
Sensitive
:
A2
No biomarker
Medulloblastoma
No biomarker
Medulloblastoma
carboplatin + cyclophosphamide + etoposide oral
Sensitive: A2 - Guideline
carboplatin + cyclophosphamide + etoposide oral
Sensitive
:
A2
carboplatin + cyclophosphamide + etoposide oral
Sensitive: A2 - Guideline
carboplatin + cyclophosphamide + etoposide oral
Sensitive
:
A2
No biomarker
Merkel Cell Carcinoma
No biomarker
Merkel Cell Carcinoma
cisplatin + etoposide oral
Sensitive: A2 - Guideline
cisplatin + etoposide oral
Sensitive
:
A2
cisplatin + etoposide oral
Sensitive: A2 - Guideline
cisplatin + etoposide oral
Sensitive
:
A2
MLL-AFF1 fusion
Acute Lymphocytic Leukemia
MLL-AFF1 fusion
Acute Lymphocytic Leukemia
etoposide oral
Sensitive: B - Late Trials
etoposide oral
Sensitive
:
B
etoposide oral
Sensitive: B - Late Trials
etoposide oral
Sensitive
:
B
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
etoposide oral
Sensitive: C3 – Early Trials
etoposide oral
Sensitive
:
C3
etoposide oral
Sensitive: C3 – Early Trials
etoposide oral
Sensitive
:
C3
Chr t(22)
Germ Cell Tumors
Chr t(22)
Germ Cell Tumors
cisplatin + ifosfamide + etoposide oral + mesna
Sensitive: C4 – Case Studies
cisplatin + ifosfamide + etoposide oral + mesna
Sensitive
:
C4
cisplatin + ifosfamide + etoposide oral + mesna
Sensitive: C4 – Case Studies
cisplatin + ifosfamide + etoposide oral + mesna
Sensitive
:
C4
EGFR exon 19 deletion + EGFR T790M
Small Cell Lung Cancer
EGFR exon 19 deletion + EGFR T790M
Small Cell Lung Cancer
etoposide oral
Sensitive: C4 – Case Studies
etoposide oral
Sensitive
:
C4
etoposide oral
Sensitive: C4 – Case Studies
etoposide oral
Sensitive
:
C4
TOP2A overexpression
Adrenal Cortex Carcinoma
TOP2A overexpression
Adrenal Cortex Carcinoma
etoposide oral
Sensitive: D – Preclinical
etoposide oral
Sensitive
:
D
etoposide oral
Sensitive: D – Preclinical
etoposide oral
Sensitive
:
D
PLAC8 overexpression
Germ Cell Tumors
PLAC8 overexpression
Germ Cell Tumors
etoposide oral
Resistant: D – Preclinical
etoposide oral
Resistant
:
D
etoposide oral
Resistant: D – Preclinical
etoposide oral
Resistant
:
D
CSMD3 mutation
Small Cell Lung Cancer
CSMD3 mutation
Small Cell Lung Cancer
etoposide oral
Resistant: D – Preclinical
etoposide oral
Resistant
:
D
etoposide oral
Resistant: D – Preclinical
etoposide oral
Resistant
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login